Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50-Day Moving Average – Here’s Why

Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.79 and traded as low as $2.60. Vistagen Therapeutics shares last traded at $2.70, with a volume of 118,758 shares traded.

Vistagen Therapeutics Trading Down 2.2 %

The company has a market cap of $75.17 million, a PE ratio of -2.18 and a beta of 0.77. The firm’s 50-day simple moving average is $2.79 and its two-hundred day simple moving average is $3.00.

Hedge Funds Weigh In On Vistagen Therapeutics

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC increased its stake in shares of Vistagen Therapeutics by 30.5% in the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after acquiring an additional 4,722 shares during the period. R Squared Ltd acquired a new stake in Vistagen Therapeutics during the fourth quarter worth about $25,000. Jane Street Group LLC purchased a new position in Vistagen Therapeutics during the third quarter valued at approximately $59,000. HighTower Advisors LLC acquired a new position in Vistagen Therapeutics in the third quarter valued at approximately $64,000. Finally, Prosperity Wealth Management Inc. acquired a new position in Vistagen Therapeutics in the fourth quarter valued at approximately $86,000. 78.39% of the stock is owned by institutional investors and hedge funds.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.